YARTEMLEA
LaunchmAbnarsoplimab
BLAINTRAVENOUSINJECTIONPriority Review
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YARTEMLEA (narsoplimab) is a monoclonal antibody approved via BLA in December 2025, currently in launch phase. The mechanism of action and specific indications are not yet detailed in available data. This is an intravenous biologic therapy representing a novel entry into its target market.
Growth
Recent launch phase with moderate competitive pressure (30%) suggests an active commercial build-out and expanding sales infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
YARTEMLEA launch phase positions roles in brand management, field sales, and medical affairs as primary opportunities. Early career visibility may be limited due to zero linked jobs currently posted, suggesting hiring may accelerate post-launch.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.